APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting ESAs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Long-acting ESAs Market Analysis and Forecast 2026-2032

29 December 2025194 pages

Choose your research edition.

Industry ResearchLong-acting ESAs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting ESAs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Long-acting ESAs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting ESAs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting ESAs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Long-acting ESAs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Long-acting ESAs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Long-acting ESAs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Long-acting ESAs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Long-acting ESAs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Long-acting ESAs include Amgen, Cipla, CKD Pharma, Dr. Reddy's Laboratories, Kissei Pharmaceutical, Kyowa Hakko Kirin, Sanwa Kagaku Kenkyusho, Torrent Pharmaceuticals and Hansoh Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Long-acting ESAs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Long-acting ESAs, also provides the sales of main regions and countries. Of the upcoming market potential for Long-acting ESAs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Long-acting ESAs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Long-acting ESAs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Long-acting ESAs sales, projected growth trends, production technology, application and end-user industry.

Long-acting ESAs Segment by Company

Amgen

Cipla

CKD Pharma

Dr. Reddy's Laboratories

Kissei Pharmaceutical

Kyowa Hakko Kirin

Sanwa Kagaku Kenkyusho

Torrent Pharmaceuticals

Hansoh Pharma

Roche

Kyowa Kirin

Long-acting ESAs Segment by Type

Pegmolesatide

Methoxy Polyethylene Glycol-Epoetin Beta

Darbepoetin Alfa

Long-acting ESAs Segment by Application

Renal Anemia

Cancer

Other

Long-acting ESAs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting ESAs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting ESAs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting ESAs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Long-acting ESAs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Long-acting ESAs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Long-acting ESAs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Long-acting ESAs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pegmolesatide Major Manufacturers Table 3. Methoxy Polyethylene Glycol-Epoetin Beta Major Manufacturers Table 4. Darbepoetin Alfa Major Manufacturers Table 5. Global Long-acting ESAs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Renal Anemia Major Manufacturers Table 7. Cancer Major Manufacturers Table 8. Other Major Manufacturers Table 9. Long-acting ESAs Industry Trends Table 10. Long-acting ESAs Industry Drivers Table 11. Long-acting ESAs Industry Opportunities and Challenges Table 12. Long-acting ESAs Industry Restraints Table 13. Global Long-acting ESAs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 14. Global Long-acting ESAs Revenue by Region (2021-2026) & (US$ Million) Table 15. Global Long-acting ESAs Revenue by Region (2027-2032) & (US$ Million) Table 16. Global Long-acting ESAs Revenue Market Share by Region (2021-2026) Table 17. Global Long-acting ESAs Revenue Market Share by Region (2027-2032) Table 18. Global Long-acting ESAs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 19. Global Long-acting ESAs Sales by Region (2021-2026) & (K Units) Table 20. Global Long-acting ESAs Sales by Region (2027-2032) & (K Units) Table 21. Global Long-acting ESAs Sales Market Share by Region (2021-2026) Table 22. Global Long-acting ESAs Sales Market Share by Region (2027-2032) Table 23. Global Long-acting ESAs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Long-acting ESAs Revenue Market Share by Manufacturers (2021-2026) Table 25. Global Long-acting ESAs Sales by Manufacturers (US$ Million) & (2021-2026) Table 26. Global Long-acting ESAs Sales Market Share by Manufacturers (2021-2026) Table 27. Global Long-acting ESAs Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 28. Global Long-acting ESAs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 29. Global Long-acting ESAs Key Manufacturers Manufacturing Sites & Headquarters Table 30. Global Long-acting ESAs Manufacturers, Product Type & Application Table 31. Global Long-acting ESAs Manufacturers' Establishment Date Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 33. Global Long-acting ESAs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 34. Global Long-acting ESAs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 36. Global Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 37. Global Long-acting ESAs Revenue Market Share by Type (2021-2026) Table 38. Global Long-acting ESAs Revenue Market Share by Type (2027-2032) Table 39. Global Long-acting ESAs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 40. Global Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 41. Global Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 42. Global Long-acting ESAs Sales Market Share by Type (2021-2026) Table 43. Global Long-acting ESAs Sales Market Share by Type (2027-2032) Table 44. Global Long-acting ESAs Price by Type (2021-2026) & (US$/Unit) Table 45. Global Long-acting ESAs Price by Type (2027-2032) & (US$/Unit) Table 46. Global Long-acting ESAs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 48. Global Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 49. Global Long-acting ESAs Revenue Market Share by Application (2021-2026) Table 50. Global Long-acting ESAs Revenue Market Share by Application (2027-2032) Table 51. Global Long-acting ESAs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 52. Global Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 53. Global Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 54. Global Long-acting ESAs Sales Market Share by Application (2021-2026) Table 55. Global Long-acting ESAs Sales Market Share by Application (2027-2032) Table 56. Global Long-acting ESAs Price by Application (2021-2026) & (US$/Unit) Table 57. Global Long-acting ESAs Price by Application (2027-2032) & (US$/Unit) Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Amgen Long-acting ESAs Product Portfolio Table 62. Amgen Recent Development Table 63. Cipla Company Information Table 64. Cipla Business Overview Table 65. Cipla Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Cipla Long-acting ESAs Product Portfolio Table 67. Cipla Recent Development Table 68. CKD Pharma Company Information Table 69. CKD Pharma Business Overview Table 70. CKD Pharma Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. CKD Pharma Long-acting ESAs Product Portfolio Table 72. CKD Pharma Recent Development Table 73. Dr. Reddy's Laboratories Company Information Table 74. Dr. Reddy's Laboratories Business Overview Table 75. Dr. Reddy's Laboratories Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio Table 77. Dr. Reddy's Laboratories Recent Development Table 78. Kissei Pharmaceutical Company Information Table 79. Kissei Pharmaceutical Business Overview Table 80. Kissei Pharmaceutical Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Kissei Pharmaceutical Long-acting ESAs Product Portfolio Table 82. Kissei Pharmaceutical Recent Development Table 83. Kyowa Hakko Kirin Company Information Table 84. Kyowa Hakko Kirin Business Overview Table 85. Kyowa Hakko Kirin Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Kyowa Hakko Kirin Long-acting ESAs Product Portfolio Table 87. Kyowa Hakko Kirin Recent Development Table 88. Sanwa Kagaku Kenkyusho Company Information Table 89. Sanwa Kagaku Kenkyusho Business Overview Table 90. Sanwa Kagaku Kenkyusho Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio Table 92. Sanwa Kagaku Kenkyusho Recent Development Table 93. Torrent Pharmaceuticals Company Information Table 94. Torrent Pharmaceuticals Business Overview Table 95. Torrent Pharmaceuticals Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Torrent Pharmaceuticals Long-acting ESAs Product Portfolio Table 97. Torrent Pharmaceuticals Recent Development Table 98. Hansoh Pharma Company Information Table 99. Hansoh Pharma Business Overview Table 100. Hansoh Pharma Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Hansoh Pharma Long-acting ESAs Product Portfolio Table 102. Hansoh Pharma Recent Development Table 103. Roche Company Information Table 104. Roche Business Overview Table 105. Roche Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Roche Long-acting ESAs Product Portfolio Table 107. Roche Recent Development Table 108. Kyowa Kirin Company Information Table 109. Kyowa Kirin Business Overview Table 110. Kyowa Kirin Long-acting ESAs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Kyowa Kirin Long-acting ESAs Product Portfolio Table 112. Kyowa Kirin Recent Development Table 113. North America Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 114. North America Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 115. North America Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 116. North America Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 117. North America Long-acting ESAs Sales Price by Type (2021-2026) & (US$/Unit) Table 118. North America Long-acting ESAs Sales Price by Type (2027-2032) & (US$/Unit) Table 119. North America Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 120. North America Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 121. North America Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 122. North America Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 123. North America Long-acting ESAs Sales Price by Application (2021-2026) & (US$/Unit) Table 124. North America Long-acting ESAs Sales Price by Application (2027-2032) & (US$/Unit) Table 125. North America Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Long-acting ESAs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 127. North America Long-acting ESAs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 128. North America Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 129. North America Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 130. North America Long-acting ESAs Sales by Country (2027-2032) & (K Units) Table 131. North America Long-acting ESAs Sales Price by Country (2021-2026) & (US$/Unit) Table 132. North America Long-acting ESAs Sales Price by Country (2027-2032) & (US$/Unit) Table 133. United States Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 134. Canada Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 135. Mexico Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 136. Europe Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 137. Europe Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 138. Europe Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 139. Europe Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 140. Europe Long-acting ESAs Sales Price by Type (2021-2026) & (US$/Unit) Table 141. Europe Long-acting ESAs Sales Price by Type (2027-2032) & (US$/Unit) Table 142. Europe Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 143. Europe Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 144. Europe Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 145. Europe Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 146. Europe Long-acting ESAs Sales Price by Application (2021-2026) & (US$/Unit) Table 147. Europe Long-acting ESAs Sales Price by Application (2027-2032) & (US$/Unit) Table 148. Europe Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Long-acting ESAs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 150. Europe Long-acting ESAs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 151. Europe Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 152. Europe Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 153. Europe Long-acting ESAs Sales by Country (2027-2032) & (K Units) Table 154. Europe Long-acting ESAs Sales Price by Country (2021-2026) & (US$/Unit) Table 155. Europe Long-acting ESAs Sales Price by Country (2027-2032) & (US$/Unit) Table 156. Germany Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 157. France Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 158. U.K. Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 159. Italy Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 160. Russia Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 161. Spain Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 162. Netherlands Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 163. Switzerland Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 164. Sweden Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 165. Poland Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 166. China Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 167. China Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 168. China Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 169. China Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 170. China Long-acting ESAs Sales Price by Type (2021-2026) & (US$/Unit) Table 171. China Long-acting ESAs Sales Price by Type (2027-2032) & (US$/Unit) Table 172. China Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 173. China Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 174. China Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 175. China Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 176. China Long-acting ESAs Sales Price by Application (2021-2026) & (US$/Unit) Table 177. China Long-acting ESAs Sales Price by Application (2027-2032) & (US$/Unit) Table 178. Asia Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 179. Asia Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 180. Asia Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 181. Asia Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 182. Asia Long-acting ESAs Sales Price by Type (2021-2026) & (US$/Unit) Table 183. Asia Long-acting ESAs Sales Price by Type (2027-2032) & (US$/Unit) Table 184. Asia Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 185. Asia Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 186. Asia Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 187. Asia Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 188. Asia Long-acting ESAs Sales Price by Application (2021-2026) & (US$/Unit) Table 189. Asia Long-acting ESAs Sales Price by Application (2027-2032) & (US$/Unit) Table 190. Asia Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. Asia Long-acting ESAs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 192. Asia Long-acting ESAs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 193. Asia Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 194. Asia Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 195. Asia Long-acting ESAs Sales by Country (2027-2032) & (K Units) Table 196. Asia Long-acting ESAs Sales Price by Country (2021-2026) & (US$/Unit) Table 197. Asia Long-acting ESAs Sales Price by Country (2027-2032) & (US$/Unit) Table 198. Japan Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 199. South Korea Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 200. India Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 201. Australia Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 202. Taiwan Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 203. Southeast Asia Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 204. SAMEA Long-acting ESAs Revenue by Type (2021-2026) & (US$ Million) Table 205. SAMEA Long-acting ESAs Revenue by Type (2027-2032) & (US$ Million) Table 206. SAMEA Long-acting ESAs Sales by Type (2021-2026) & (K Units) Table 207. SAMEA Long-acting ESAs Sales by Type (2027-2032) & (K Units) Table 208. SAMEA Long-acting ESAs Sales Price by Type (2021-2026) & (US$/Unit) Table 209. SAMEA Long-acting ESAs Sales Price by Type (2027-2032) & (US$/Unit) Table 210. SAMEA Long-acting ESAs Revenue by Application (2021-2026) & (US$ Million) Table 211. SAMEA Long-acting ESAs Revenue by Application (2027-2032) & (US$ Million) Table 212. SAMEA Long-acting ESAs Sales by Application (2021-2026) & (K Units) Table 213. SAMEA Long-acting ESAs Sales by Application (2027-2032) & (K Units) Table 214. SAMEA Long-acting ESAs Sales Price by Application (2021-2026) & (US$/Unit) Table 215. SAMEA Long-acting ESAs Sales Price by Application (2027-2032) & (US$/Unit) Table 216. SAMEA Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 217. SAMEA Long-acting ESAs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 218. SAMEA Long-acting ESAs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 219. SAMEA Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 220. SAMEA Long-acting ESAs Sales by Country (2021-2026) & (K Units) Table 221. SAMEA Long-acting ESAs Sales by Country (2027-2032) & (K Units) Table 222. SAMEA Long-acting ESAs Sales Price by Country (2021-2026) & (US$/Unit) Table 223. SAMEA Long-acting ESAs Sales Price by Country (2027-2032) & (US$/Unit) Table 224. Brazil Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 225. Argentina Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 226. Chile Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 227. Colombia Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 228. Peru Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 229. Saudi Arabia Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 230. Israel Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 231. UAE Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 232. Turkey Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 233. Iran Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 234. Egypt Long-acting ESAs Revenue (2021-2032) & (US$ Million) Table 235. Key Raw Materials Table 236. Raw Materials Key Suppliers Table 237. Long-acting ESAs Distributors List Table 238. Long-acting ESAs Customers List Table 239. Research Programs/Design for This Report Table 240. Authors List of This Report Table 241. Secondary Sources Table 242. Primary Sources List of Figures Figure 1. Long-acting ESAs Image Figure 2. Global Long-acting ESAs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting ESAs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pegmolesatide Image Figure 5. Methoxy Polyethylene Glycol-Epoetin Beta Image Figure 6. Darbepoetin Alfa Image Figure 7. Global Long-acting ESAs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Long-acting ESAs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Renal Anemia Image Figure 10. Cancer Image Figure 11. Other Image Figure 12. Global Long-acting ESAs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Long-acting ESAs Revenue (2021-2032) & (US$ Million) Figure 14. Global Long-acting ESAs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 15. Global Long-acting ESAs Revenue Market Share by Region: 2025 Versus 2032 Figure 16. Global Long-acting ESAs Revenue Market Share by Region (2021-2032) Figure 17. Global Long-acting ESAs Sales (2021-2032) & (K Units) Figure 18. Global Long-acting ESAs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 19. Global Long-acting ESAs Sales Market Share by Region (2021-2032) Figure 20. US & Canada & Mexico Long-acting ESAs Sales YoY (2021-2032) & (K Units) Figure 21. Europe Long-acting ESAs Sales YoY (2021-2032) & (K Units) Figure 22. China Long-acting ESAs Sales YoY (2021-2032) & (K Units) Figure 23. Asia (Excluding China) Long-acting ESAs Sales YoY (2021-2032) & (K Units) Figure 24. South America, Middle East and Africa Long-acting ESAs Sales YoY (2021-2032) & (K Units) Figure 25. Global Long-acting ESAs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 26. Global Long-acting ESAs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 28. Global Long-acting ESAs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Long-acting ESAs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 30. Global Long-acting ESAs Revenue Market Share by Type (2021-2032) Figure 31. Global Long-acting ESAs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 32. Global Long-acting ESAs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Long-acting ESAs Sales Market Share by Type (2021-2032) Figure 34. Global Long-acting ESAs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 35. Global Long-acting ESAs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 36. Global Long-acting ESAs Revenue Market Share by Application (2021-2032) Figure 37. Global Long-acting ESAs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 38. Global Long-acting ESAs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Long-acting ESAs Sales Market Share by Application (2021-2032) Figure 40. North America Long-acting ESAs Revenue Share by Type (2021-2032) Figure 41. North America Long-acting ESAs Sales Share by Type (2021-2032) Figure 42. North America Long-acting ESAs Revenue Share by Application (2021-2032) Figure 43. North America Long-acting ESAs Sales Share by Application (2021-2032) Figure 44. North America Long-acting ESAs Revenue Share by Country (2021-2032) Figure 45. North America Long-acting ESAs Sales Share by Country (2021-2032) Figure 46. Europe Long-acting ESAs Revenue Share by Type (2021-2032) Figure 47. Europe Long-acting ESAs Sales Share by Type (2021-2032) Figure 48. Europe Long-acting ESAs Revenue Share by Application (2021-2032) Figure 49. Europe Long-acting ESAs Sales Share by Application (2021-2032) Figure 50. Europe Long-acting ESAs Revenue Share by Country (2021-2032) Figure 51. Europe Long-acting ESAs Sales Share by Country (2021-2032) Figure 52. China Long-acting ESAs Revenue Share by Type (2021-2032) Figure 53. China Long-acting ESAs Sales Share by Type (2021-2032) Figure 54. China Long-acting ESAs Revenue Share by Application (2021-2032) Figure 55. China Long-acting ESAs Sales Share by Application (2021-2032) Figure 56. Asia Long-acting ESAs Revenue Share by Type (2021-2032) Figure 57. Asia Long-acting ESAs Sales Share by Type (2021-2032) Figure 58. Asia Long-acting ESAs Revenue Share by Application (2021-2032) Figure 59. Asia Long-acting ESAs Sales Share by Application (2021-2032) Figure 60. Asia Long-acting ESAs Revenue Share by Country (2021-2032) Figure 61. Asia Long-acting ESAs Sales Share by Country (2021-2032) Figure 62. SAMEA Long-acting ESAs Revenue Share by Type (2021-2032) Figure 63. SAMEA Long-acting ESAs Sales Share by Type (2021-2032) Figure 64. SAMEA Long-acting ESAs Revenue Share by Application (2021-2032) Figure 65. SAMEA Long-acting ESAs Sales Share by Application (2021-2032) Figure 66. SAMEA Long-acting ESAs Revenue Share by Country (2021-2032) Figure 67. SAMEA Long-acting ESAs Sales Share by Country (2021-2032) Figure 68. Long-acting ESAs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Long-acting ESAs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Pegmolesatide
  • Methoxy Polyethylene Glycol-Epoetin Beta
  • Darbepoetin Alfa
Applications
  • Renal Anemia
  • Cancer
  • Other
Companies covered
  • Amgen
  • Cipla
  • CKD Pharma
  • Dr. Reddy's Laboratories
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • Sanwa Kagaku Kenkyusho
  • Torrent Pharmaceuticals
  • Hansoh Pharma
  • Roche
  • Kyowa Kirin

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Long-acting ESAs Market by Type
  3. 1.2.1 Global Long-acting ESAs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pegmolesatide
  5. 1.2.3 Methoxy Polyethylene Glycol-Epoetin Beta
  6. 1.2.4 Darbepoetin Alfa
  7. 1.3 Long-acting ESAs Market by Application
  8. 1.3.1 Global Long-acting ESAs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Renal Anemia
  10. 1.3.3 Cancer
  11. 1.3.4 Other
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Long-acting ESAs Market Dynamics
  1. 2.1 Long-acting ESAs Industry Trends
  2. 2.2 Long-acting ESAs Industry Drivers
  3. 2.3 Long-acting ESAs Industry Opportunities and Challenges
  4. 2.4 Long-acting ESAs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Long-acting ESAs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Long-acting ESAs Revenue by Region
  3. 3.2.1 Global Long-acting ESAs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Long-acting ESAs Revenue by Region (2021-2026)
  5. 3.2.3 Global Long-acting ESAs Revenue by Region (2027-2032)
  6. 3.2.4 Global Long-acting ESAs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Long-acting ESAs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Long-acting ESAs Sales by Region
  9. 3.4.1 Global Long-acting ESAs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Long-acting ESAs Sales by Region (2021-2026)
  11. 3.4.3 Global Long-acting ESAs Sales by Region (2027-2032)
  12. 3.4.4 Global Long-acting ESAs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Long-acting ESAs Revenue by Manufacturers
  2. 4.1.1 Global Long-acting ESAs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Long-acting ESAs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Long-acting ESAs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Long-acting ESAs Sales by Manufacturers
  6. 4.2.1 Global Long-acting ESAs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Long-acting ESAs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Long-acting ESAs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Long-acting ESAs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Long-acting ESAs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Long-acting ESAs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Long-acting ESAs Manufacturers, Product Type & Application
  13. 4.7 Global Long-acting ESAs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Long-acting ESAs Market CR5 and HHI
  16. 4.8.2 2025 Long-acting ESAs Tier 1, Tier 2, and Tier 3
5 Long-acting ESAs Market by Type
  1. 5.1 Global Long-acting ESAs Revenue by Type
  2. 5.1.1 Global Long-acting ESAs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Long-acting ESAs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Long-acting ESAs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Long-acting ESAs Sales by Type
  6. 5.2.1 Global Long-acting ESAs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting ESAs Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Long-acting ESAs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Long-acting ESAs Price by Type
6 Long-acting ESAs Market by Application
  1. 6.1 Global Long-acting ESAs Revenue by Application
  2. 6.1.1 Global Long-acting ESAs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Long-acting ESAs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Long-acting ESAs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Long-acting ESAs Sales by Application
  6. 6.2.1 Global Long-acting ESAs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Long-acting ESAs Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Long-acting ESAs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Long-acting ESAs Price by Application
7 Company Profiles
  1. 7.1 Amgen
  2. 7.1.1 Amgen Company Information
  3. 7.1.2 Amgen Business Overview
  4. 7.1.3 Amgen Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Amgen Long-acting ESAs Product Portfolio
  6. 7.1.5 Amgen Recent Developments
  7. 7.2 Cipla
  8. 7.2.1 Cipla Company Information
  9. 7.2.2 Cipla Business Overview
  10. 7.2.3 Cipla Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Cipla Long-acting ESAs Product Portfolio
  12. 7.2.5 Cipla Recent Developments
  13. 7.3 CKD Pharma
  14. 7.3.1 CKD Pharma Company Information
  15. 7.3.2 CKD Pharma Business Overview
  16. 7.3.3 CKD Pharma Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 CKD Pharma Long-acting ESAs Product Portfolio
  18. 7.3.5 CKD Pharma Recent Developments
  19. 7.4 Dr. Reddy's Laboratories
  20. 7.4.1 Dr. Reddy's Laboratories Company Information
  21. 7.4.2 Dr. Reddy's Laboratories Business Overview
  22. 7.4.3 Dr. Reddy's Laboratories Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Dr. Reddy's Laboratories Long-acting ESAs Product Portfolio
  24. 7.4.5 Dr. Reddy's Laboratories Recent Developments
  25. 7.5 Kissei Pharmaceutical
  26. 7.5.1 Kissei Pharmaceutical Company Information
  27. 7.5.2 Kissei Pharmaceutical Business Overview
  28. 7.5.3 Kissei Pharmaceutical Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Kissei Pharmaceutical Long-acting ESAs Product Portfolio
  30. 7.5.5 Kissei Pharmaceutical Recent Developments
  31. 7.6 Kyowa Hakko Kirin
  32. 7.6.1 Kyowa Hakko Kirin Company Information
  33. 7.6.2 Kyowa Hakko Kirin Business Overview
  34. 7.6.3 Kyowa Hakko Kirin Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kyowa Hakko Kirin Long-acting ESAs Product Portfolio
  36. 7.6.5 Kyowa Hakko Kirin Recent Developments
  37. 7.7 Sanwa Kagaku Kenkyusho
  38. 7.7.1 Sanwa Kagaku Kenkyusho Company Information
  39. 7.7.2 Sanwa Kagaku Kenkyusho Business Overview
  40. 7.7.3 Sanwa Kagaku Kenkyusho Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Sanwa Kagaku Kenkyusho Long-acting ESAs Product Portfolio
  42. 7.7.5 Sanwa Kagaku Kenkyusho Recent Developments
  43. 7.8 Torrent Pharmaceuticals
  44. 7.8.1 Torrent Pharmaceuticals Company Information
  45. 7.8.2 Torrent Pharmaceuticals Business Overview
  46. 7.8.3 Torrent Pharmaceuticals Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Torrent Pharmaceuticals Long-acting ESAs Product Portfolio
  48. 7.8.5 Torrent Pharmaceuticals Recent Developments
  49. 7.9 Hansoh Pharma
  50. 7.9.1 Hansoh Pharma Company Information
  51. 7.9.2 Hansoh Pharma Business Overview
  52. 7.9.3 Hansoh Pharma Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Hansoh Pharma Long-acting ESAs Product Portfolio
  54. 7.9.5 Hansoh Pharma Recent Developments
  55. 7.10 Roche
  56. 7.10.1 Roche Company Information
  57. 7.10.2 Roche Business Overview
  58. 7.10.3 Roche Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Roche Long-acting ESAs Product Portfolio
  60. 7.10.5 Roche Recent Developments
  61. 7.11 Kyowa Kirin
  62. 7.11.1 Kyowa Kirin Company Information
  63. 7.11.2 Kyowa Kirin Business Overview
  64. 7.11.3 Kyowa Kirin Long-acting ESAs Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Kyowa Kirin Long-acting ESAs Product Portfolio
  66. 7.11.5 Kyowa Kirin Recent Developments
8 North America
  1. 8.1 North America Long-acting ESAs Market Size by Type
  2. 8.1.1 North America Long-acting ESAs Revenue by Type (2021-2032)
  3. 8.1.2 North America Long-acting ESAs Sales by Type (2021-2032)
  4. 8.1.3 North America Long-acting ESAs Price by Type (2021-2032)
  5. 8.2 North America Long-acting ESAs Market Size by Application
  6. 8.2.1 North America Long-acting ESAs Revenue by Application (2021-2032)
  7. 8.2.2 North America Long-acting ESAs Sales by Application (2021-2032)
  8. 8.2.3 North America Long-acting ESAs Price by Application (2021-2032)
  9. 8.3 North America Long-acting ESAs Market Size by Country
  10. 8.3.1 North America Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Long-acting ESAs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Long-acting ESAs Market Size by Type
  2. 9.1.1 Europe Long-acting ESAs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Long-acting ESAs Sales by Type (2021-2032)
  4. 9.1.3 Europe Long-acting ESAs Price by Type (2021-2032)
  5. 9.2 Europe Long-acting ESAs Market Size by Application
  6. 9.2.1 Europe Long-acting ESAs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Long-acting ESAs Sales by Application (2021-2032)
  8. 9.2.3 Europe Long-acting ESAs Price by Application (2021-2032)
  9. 9.3 Europe Long-acting ESAs Market Size by Country
  10. 9.3.1 Europe Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Long-acting ESAs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Long-acting ESAs Market Size by Type
  2. 10.1.1 China Long-acting ESAs Revenue by Type (2021-2032)
  3. 10.1.2 China Long-acting ESAs Sales by Type (2021-2032)
  4. 10.1.3 China Long-acting ESAs Price by Type (2021-2032)
  5. 10.2 China Long-acting ESAs Market Size by Application
  6. 10.2.1 China Long-acting ESAs Revenue by Application (2021-2032)
  7. 10.2.2 China Long-acting ESAs Sales by Application (2021-2032)
  8. 10.2.3 China Long-acting ESAs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Long-acting ESAs Market Size by Type
  2. 11.1.1 Asia Long-acting ESAs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Long-acting ESAs Sales by Type (2021-2032)
  4. 11.1.3 Asia Long-acting ESAs Price by Type (2021-2032)
  5. 11.2 Asia Long-acting ESAs Market Size by Application
  6. 11.2.1 Asia Long-acting ESAs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Long-acting ESAs Sales by Application (2021-2032)
  8. 11.2.3 Asia Long-acting ESAs Price by Application (2021-2032)
  9. 11.3 Asia Long-acting ESAs Market Size by Country
  10. 11.3.1 Asia Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Long-acting ESAs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Long-acting ESAs Market Size by Type
  2. 12.1.1 SAMEA Long-acting ESAs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Long-acting ESAs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Long-acting ESAs Price by Type (2021-2032)
  5. 12.2 SAMEA Long-acting ESAs Market Size by Application
  6. 12.2.1 SAMEA Long-acting ESAs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Long-acting ESAs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Long-acting ESAs Price by Application (2021-2032)
  9. 12.3 SAMEA Long-acting ESAs Market Size by Country
  10. 12.3.1 SAMEA Long-acting ESAs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Long-acting ESAs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Long-acting ESAs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Long-acting ESAs Value Chain Analysis
  2. 13.1.1 Long-acting ESAs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Long-acting ESAs Production Mode & Process
  6. 13.2 Long-acting ESAs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Long-acting ESAs Distributors
  9. 13.2.3 Long-acting ESAs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst